{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:26:37Z","timestamp":1777793197684,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["RG 38\/2566"],"award-info":[{"award-number":["RG 38\/2566"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.genhosppsych.2024.12.003","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T19:37:50Z","timestamp":1733513870000},"page":"4-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"92","author":[{"given":"Nahathai","family":"Limveeraprajak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Worawut","family":"Makkapavee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surinporn","family":"Likhitsathian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manit","family":"Srisurapanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0005","first-page":"22","article-title":"Prevalence of Parkinson\u2019s disease-induced psychosis in a large U.S. managed care population","author":"Holt","year":"2010","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/08919887211018280","article-title":"Psychosis in Parkinson\u2019s disease: current treatment options and impact on patients and caregivers","volume":"34","author":"Segal","year":"2021","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0015","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with Parkinson\u2019s disease (1991-2010)","volume":"12","author":"Stang","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40263-024-01084-1","article-title":"On the optimal diagnosis and the evolving role of Pimavanserin in Parkinson\u2019s disease psychosis","volume":"38","author":"Pagan","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1176\/appi.ajp.20220519","article-title":"The safety of Pimavanserin for Parkinson\u2019s disease and efforts to reduce antipsychotics for people with dementia","volume":"179","author":"Schneider","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0030","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of hospitalization and death associated with Pimavanserin use in older adults with Parkinson disease","volume":"97","author":"Hwang","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.genhosppsych.2024.02.008","article-title":"Second-generation antipsychotics for Parkinson\u2019s disease psychosis: a systematic review and network meta-analysis","volume":"87","author":"Srisurapanont","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson\u2019s disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","article-title":"The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies","volume":"50","author":"Li","year":"2020","journal-title":"Psychol Med"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40266-013-0144-2","article-title":"Adverse effects of clozapine in older patients: epidemiology, prevention and management","volume":"31","author":"Bishara","year":"2014","journal-title":"Drugs Aging"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajp.2018.03.008","article-title":"Clozapine use in geriatric patients- challenges","volume":"33","author":"Mukku","year":"2018","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0070","first-page":"75","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9740\/mhc.2020.05.070","article-title":"Clozapine and hematologic adverse reactions: impact of the risk evaluation and mitigation strategy program","volume":"10","author":"Borrelli","year":"2020","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST action","volume":"7","author":"Fioredda","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0100","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0105","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0120","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JS9.0000000000000114","article-title":"Should the reporting certainty of evidence for meta-analysis of observational studies using GRADE be revisited?","volume":"109","author":"Yousefifard","year":"2023","journal-title":"Int J Surg Lond Engl"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0130","article-title":"The effect of clozapine on tremor in patients with parkinson\u2019s disease who were initiated clozapine for psychotic symptoms","volume":"51","author":"Akarsu","year":"2013","journal-title":"Psikotik Semptomlar\u0131 Sebebi Ile Klozapin Ba\u015flanm\u0131\u015f Olan Park Hast Klozapinin Tremor \u00dczerine Etkisi"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0135","first-page":"7","article-title":"Clozapine for acute and maintenance treatment of psychosis in Parkinson\u2019s disease","author":"Chacko","year":"1995","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0140","series-title":"Use of clozapine for psychiatric complications of Parkinson\u2019s disease. Clozapine Dans Trait Manif Psychiatr Mal Park","first-page":"151","author":"Diederich","year":"1995"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0145","series-title":"Clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease: results of the 12 week open label extension in the PSYCLOPS trial","first-page":"16","author":"Factor","year":"2001"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.44.3_Part_1.544","article-title":"Clozapine: a 2-year open trial in Parkinson\u2019s disease patients with psychosis","volume":"44","author":"Factor","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0155","first-page":"19","article-title":"Long-term outcome of clozapine use for psychosis in parkinsonian patients","author":"Fernandez","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0160","first-page":"66","article-title":"Use of clozapine in Brazilian patients with Parkinson\u2019s disease","author":"Gomide","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0165","first-page":"9","article-title":"An eight-year clinic experience with clozapine use in a Parkinson\u2019s disease clinic setting","author":"Hack","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.41.10.1699","article-title":"Clozapine is beneficial for psychosis in Parkinson\u2019s disease","volume":"41","author":"Kahn","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0175","first-page":"26","article-title":"Clozapine in Parkinson\u2019s disease psychosis: 5-year follow-up review","author":"Klein","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0180","first-page":"29","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for parkinson\u2019s disease psychosis","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0185","first-page":"353","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease","author":"Pollak","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.45.3.432","article-title":"Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson\u2019s disease","volume":"45","author":"Rabey","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0195","first-page":"20","article-title":"Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson\u2019s disease","author":"Ruggieri","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0200","first-page":"109","article-title":"Clozapine: efficacy for Parkinson disease psychosis in patients refractory to pimavanserin","author":"Thames","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0205","first-page":"33","article-title":"Current use of clozapine in Parkinson disease and related disorders","author":"Thomas","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0210","first-page":"13","article-title":"Clozapine use in Parkinson\u2019s disease: a retrospective analysis of a large multicentered clinical experience","author":"Trosch","year":"1998","journal-title":"Mov Disord"},{"issue":"Suppl. 3","key":"10.1016\/j.genhosppsych.2024.12.003_bb0215","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.genhosppsych.2024.12.003_bb0220","first-page":"38","article-title":"Maximizing clozapine therapy: managing side effects","volume":"59","author":"Lieberman","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiol Camb Mass"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0230","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12874-018-0531-9","article-title":"Meta-analysis of binary outcomes via generalized linear mixed models: a simulation study","volume":"18","author":"Bakbergenuly","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0235","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/jcm9061808","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis in elderly patients","volume":"9","author":"Lorenzo-Villalba","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.genhosppsych.2024.12.003_bb0240","series-title":"Management of Safety Information from clinical trials: Report of CIOMS working group VI","author":"Council for International Organizations of MMedical SSciences (CIOMS)","year":"2005"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324002469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324002469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:09:39Z","timestamp":1777493379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834324002469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"alternative-id":["S0163834324002469"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.12.003","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}